LTS Lohmann Therapie-Systeme AG

Andernach, Germany
Transdermal Patches (TTS) Oral Thin Films (OTF) Microneedle Array Patches (MAP) Wearable/On-Body Drug Delivery Devices Nasal Sprays (via Renaissance Lakewood acquisition) Sterile Dosage Forms
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (4) ○ EMA GMP ○ MHRA GMP

Quick Facts: LTS Lohmann Therapie-Systeme AG

Signal Score
60.0/100
Quality Compliance
Assessment pending
Headquarters
Andernach, Germany
Modalities
Transdermal Patches (TTS), Oral Thin Films (OTF), Microneedle Array Patches (MAP), Wearable/On-Body Drug Delivery Devices, Nasal Sprays (via Renaissance Lakewood acquisition), Sterile Dosage Forms
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About LTS Lohmann Therapie-Systeme AG

Auto-created by AI matchmaker. Data verification pending.

Signal Score & Pillar Breakdown

Quality Compliance
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs no verified data
Sponsorsno verified data
ModalitiesTransdermal Patches (TTS), Oral Thin Films (OTF), Microneedle Array Patches (MAP), Wearable/On-Body Drug Delivery Devices, Nasal Sprays (via Renaissance Lakewood acquisition), Sterile Dosage Forms
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 60.0
Broad modality coverage (6 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press4 articles
Broad modality coverage (6 modalities)

Recent News 4 articles

news Tue, 14 Oc
LTS to Acquire Renaissance Lakewood - Contract Pharma
news Tue, 03 Se
Simtra BioPharma Solutions Appoints Chief Commercial Officer - Contract Pharma
news Mon, 12 No
LTS – Your Partner for Innovative Solutions - Pharmaceutical Business review -
news Fri, 09 Au
LTS, GRAM Enter Strategic Fill Finish Pact for Wearable Injectors - Contract Pharma

Frequently Asked Questions About LTS Lohmann Therapie-Systeme AG

What is LTS Lohmann Therapie-Systeme AG's CDMO Signal Score?
LTS Lohmann Therapie-Systeme AG has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating LTS Lohmann Therapie-Systeme AG for a manufacturing program?
Use the free AI matchmaker to compare LTS Lohmann Therapie-Systeme AG against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.